App-Quantinova.ai

Delayed toxicities with anti-PD-1 and anti-PDL-1 immune checkpoint inhibitors (ICIs).

Neil J. Shah - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

Pembrolizumab

Impact of anti-infectious and corticosteroids on immunotherapy: Nivolumab and pembrozilumab follow-up in a French study.

Jean-Philippe Metges - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

Pembrolizumab

Multicenter phase II trial of pembrolizumab (pembro) in previously-treated metastatic esophageal cancer.

Peter C. Enzinger - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Pembrolizumab

Correlation of CD8 lymphocytes in tumors and nonsynonymous mutational load with prognosis of bladder cancer patients treated with immune checkpoint inhibitors.

Boya Deng - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Pembrolizumab

Myeloid-derived suppressor cell (MDSC) kinetics following acalabrutinib and pembrolizumab treatment in platinum-resistant metastatic urothelial carcinoma (mUC).

Kristen A Batich - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

Pembrolizumab

Relationship of anaplastic thyroid cancer high tumor mutation burden and MSI-H status with response to anti-PD1 monotherapy.

Saad A. Khan - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Pembrolizumab

Profiling metastatic lesions from a pembro-refractory patient to reveal distinct genomic instabilities and non-uniform response to drug combinations, ex vivo.

Chukwuemeka Ikpeazu - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Pembrolizumab

Predicting unreported clinical trial efficacy using an ex-vivo tumor platform: Pembrolizumab+pt+5-FU vs. extreme in recurrent head and neck squamous cell carcinoma.

Munisha Smalley - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Pembrolizumab

Lung cancer immunotherapy outcomes in Hispanic patients.

Luis E. Raez - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Pembrolizumab

Use of immunotherapy (IO) supplied free of charge to cancer patients.

Rajiv Agarwal - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Pembrolizumab

Allogeneic hematopoietic stem celltransplant (HSCT) after checkpoint inhibitors (ChIs) in classic Hodgkin lymphoma (cHL): Outcome and safety in pooled analysis.

Reyad Dada - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Pembrolizumab

Horizon: An ambispective study of 663 patients who initiated pembrolizumab for advanced melanoma within the French early access program.

Nicolas Meyer - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Pembrolizumab

Safety and efficacy of combining pembrolizmumab and dose escalation/fraction de-escalation SRS for melanoma and NSCLC brain metastasis: Preliminary results from arm a of a prospective pilot trial.

Mohammad Khurram Khan - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Pembrolizumab

Pembrolizumab-induced immune related adverse events and survival outcomes in advanced melanoma.

Aleksi Emil Suo - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Pembrolizumab

Ipilimumab with anti PD-1 (nivovlumab or pembrolizumab) after progression on first line anti-PD-1 therapy for advanced melanoma.

Inderjit Mehmi - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Pembrolizumab

Discontinuation of anti-PD-1 mAb after complete response in advanced melanoma pts.

Philippe Saiag - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Pembrolizumab

Emergent renal and hepatic dysfunction (dys) in a real-world cohort of advanced melanoma (aMel) patients (pts) receiving first line (1L) immune checkpoint inhibitors (ICIs).

Susan Spillane - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Pembrolizumab

T-cell biological aging in melanoma: Impact on immunotherapeutic discontinuation.

Christin Elizabeth Burd - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Pembrolizumab

Objective response rate (ORR) and time to treatment failure (TTF) for BRAF v600 mutated metastatic melanoma (BRAF+ MM) patients receiving first-line (1L) treatment with dabrafenib/trametinib (D+T) v ipilimumab/nivolumab (I+N) and nivolumab or pembrolizumab (N/P) monotherapy at US-based community oncology practices.

Bruce A. Feinberg - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Pembrolizumab

Response assessment to anti-CTLA4 or/and anti-PD1 immunotherapy in mucosal melanomas.

Antoine Moya-Plana - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Pembrolizumab

Filters

2307 Abstracts